ATE212619T1 - Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren - Google Patents

Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren

Info

Publication number
ATE212619T1
ATE212619T1 AT97910851T AT97910851T ATE212619T1 AT E212619 T1 ATE212619 T1 AT E212619T1 AT 97910851 T AT97910851 T AT 97910851T AT 97910851 T AT97910851 T AT 97910851T AT E212619 T1 ATE212619 T1 AT E212619T1
Authority
AT
Austria
Prior art keywords
matrix metalloproteinase
alpha
metalloproteinase inhibitors
hydroxamic acid
amino sulfonyl
Prior art date
Application number
AT97910851T
Other languages
German (de)
English (en)
Inventor
Martha A Warpehoski
Mark A Mitchell
E Jon Jacobsen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE212619T1 publication Critical patent/ATE212619T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97910851T 1996-10-22 1997-10-20 Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren ATE212619T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2958596P 1996-10-22 1996-10-22
PCT/US1997/018235 WO1998017645A1 (en) 1996-10-22 1997-10-20 α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Publications (1)

Publication Number Publication Date
ATE212619T1 true ATE212619T1 (de) 2002-02-15

Family

ID=21849807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910851T ATE212619T1 (de) 1996-10-22 1997-10-20 Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren

Country Status (9)

Country Link
US (1) US5804593A (enExample)
EP (1) EP0934267B1 (enExample)
JP (1) JP2001503400A (enExample)
AT (1) ATE212619T1 (enExample)
AU (1) AU4812697A (enExample)
CA (1) CA2268418A1 (enExample)
DE (1) DE69710204T2 (enExample)
ES (1) ES2171905T3 (enExample)
WO (1) WO1998017645A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
ATE248812T1 (de) * 1997-02-03 2003-09-15 Pfizer Prod Inc Arylsulfonylhydroxamsäurederivate
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
WO2000037433A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) * 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
WO2000044723A1 (en) 1999-01-27 2000-08-03 American Cyanamid Company Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
EP1165501A1 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Alkenyl- and alkynyl-containing metalloprotease inhibitors
CN1362951A (zh) 1999-03-03 2002-08-07 宝洁公司 二杂-取代的金属蛋白酶抑制剂
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CN1610661A (zh) * 2001-11-01 2005-04-27 惠氏控股公司 用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
US7504425B2 (en) 2002-05-29 2009-03-17 Merck & Co., Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
AU2003304456A1 (en) * 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
AU2004215624B2 (en) * 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
AU2005250351A1 (en) * 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
WO2019102488A1 (en) 2017-11-27 2019-05-31 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
DK0766664T3 (da) * 1994-06-22 2000-07-31 British Biotech Pharm Metalloproteinaseinhibitorer
EP0800449B1 (de) * 1995-01-03 1999-07-07 Reinhard Eichenberger Verfahren und vorrichtung zur herstellung von verstärkungseinlagen für werkstoffverbunde, insbesondere schleif- oder trennscheiben
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) * 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
PT757984E (pt) * 1995-08-08 2003-02-28 Ono Pharmaceutical Co Derivados de acido hidroxamico uteis para inibir a gelatinase
TR199800849T2 (xx) * 1995-11-13 1998-07-21 Hoechst Aktiengesellschaft Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
HU226006B1 (en) * 1996-01-23 2008-02-28 Shionogi & Co Thiophene-sulfonylamino carboxylic and hidroxamic acid derivatives and pharmaceutical compositions with metalloproteinase inhibitory activity containing the same

Also Published As

Publication number Publication date
DE69710204D1 (en) 2002-03-14
JP2001503400A (ja) 2001-03-13
EP0934267A1 (en) 1999-08-11
EP0934267B1 (en) 2002-01-30
DE69710204T2 (de) 2002-10-24
US5804593A (en) 1998-09-08
ES2171905T3 (es) 2002-09-16
AU4812697A (en) 1998-05-15
WO1998017645A1 (en) 1998-04-30
CA2268418A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
ATE212619T1 (de) Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
DE69809187D1 (de) Metalloproteinase-Inhibitoren
ATE359264T1 (de) Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
EA200201057A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
AR097445A2 (es) Ésteres oxigenados de ácidos 4-yodo fenilamino benzhidroxámicos
EA199900366A1 (ru) Гетероарильные производные сукцинамидов и их применение в качестве ингибиторов металлопротеиназы
ES2109218T3 (es) Bis-(hidroximetil)ciclobutil-purinas y -pirimidinas.
EA200300067A1 (ru) Кристаллическая форма целекоксиба
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
ATE25078T1 (de) 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
DK0464465T3 (da) Substituerede aminoalkylbiphenylderivater, antimykotiske præparater indeholdende disse derivater og mellemprodukter til fremstilling deraf
DK220386A (da) 2-(4-benzoyl-1-piperidinyl)-alkanolderivater, fremgangsmaade til fremstilling af saadanne derivater og anvendelse af disse som laegemidler
UY24919A1 (es) Compuestos amínicos sustituidos, procedimiento de preparación, y su aplicación
DK1037868T3 (da) Alfa-Hydroxy-, amino- og halogenderivater af beta-sulfonylhydroxamsyrer som matrixmetalloproteinaseinhibitorer
NO20063090L (no) Amidopyrazolderivater
CO5540284A2 (es) Sulfonamidas
ES2485867T3 (es) Compuestos opioides de carboxamido
NO984481D0 (no) 4-((thien-3-yl)metyl) imidazolderivater med <alfa>-2-adrenoceptor agonistisk aktivitet
FI833075A0 (fi) 2-nitro-1,1-etendiaminer, foerfaranden foer deras framstaellning och deras anvaendning som laekemed
SE8500107L (sv) Nya 8-alfa-acylaminoergoline
ATE356114T1 (de) Inhibitoren von metalloproteinasen
EA199800189A1 (ru) Оптически активное производное фенилпиримидина в качестве анальгетика
EA200300926A1 (ru) Новый способ промышленного синтеза метил дисложного эфира 5-амино-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
FI861045A0 (fi) B-laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
EA199900809A1 (ru) Производные 2-(замещенный бензоил) циклоакил-1-карбоновой кислоты

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties